Tirzepatide vs. Semaglutide

Both molecules act on the incretin system. Semaglutide engages one receptor; tirzepatide engages two. That single sentence is the whole comparison at the level most articles stop at, and it is misleading, because the second receptor does not behave the way the description implies.

Structural comparison

The backbone difference is the part most summaries omit. Tirzepatide is not a GLP-1 analogue with GIP activity bolted on; it is a GIP analogue engineered to also reach the GLP-1 receptor. The starting point is different, and so is the resulting receptor behaviour.

The unbalanced dual agonism

Characterisation work published alongside the compound's development describes tirzepatide as biased. Its activity at the GIP receptor is comparable to native GIP, while its activity at the GLP-1 receptor is weaker than native GLP-1. It also shows reduced beta-arrestin recruitment at the GLP-1 receptor relative to the native ligand — a signalling bias that has been proposed to slow receptor internalisation and desensitisation.

So the accurate description is not 'twice the receptors, twice the effect'. It is a molecule with strong GIP receptor activity and comparatively restrained, differently-shaped GLP-1 receptor activity. Whether the observed clinical separation comes from the GIP arm, from the altered GLP-1 signalling, or from the combination is not established.

The GIP paradox

There is a genuine and unresolved argument in this literature that consumer-facing summaries almost never mention: both GIP receptor agonism and GIP receptor antagonism have been reported to produce favourable metabolic effects in preclinical models. Genetic and pharmacological antagonism studies pointed one direction; tirzepatide's results point the other.

The leading reconciliation is that sustained agonism functionally desensitises the GIP receptor, so a long-acting agonist may end up producing an effect closer to antagonism at the tissue level. That is a plausible hypothesis with supporting preclinical work — not a resolved mechanism. Anyone writing about tirzepatide's GIP contribution as though it were understood is ahead of the evidence.

The head-to-head evidence

SURPASS-2 — type 2 diabetes

Published in the New England Journal of Medicine in 2021, this trial randomised participants with type 2 diabetes to tirzepatide or semaglutide over 40 weeks. Reductions in glycated haemoglobin were greater across the tirzepatide groups than in the semaglutide group, with the semaglutide comparator itself reducing HbA1c by 1.86 percentage points. Mean body-weight reduction was likewise greater across the tirzepatide groups, against 5.7 kg in the comparator group.

SURMOUNT-5 — obesity without diabetes

The comparison was later run in participants with obesity and without type 2 diabetes, over 72 weeks. Tirzepatide again produced the greater mean weight reduction — roughly 20% against roughly 14% for semaglutide. The direction of the result reproduced across two different populations and two different trial designs, which is a stronger basis for a comparative statement than a single trial.

What the head-to-head data does not establish

• Mechanism. A superiority result tells you which molecule produced the larger measured change. It does not tell you which receptor arm was responsible.
• Equivalence of comparator conditions. In SURPASS-2 the semaglutide arm was not run at the highest dose later approved for weight management, and this has been a persistent point of methodological criticism.
• Individual response. Both trials report group means. Response distributions in this class are wide, and a difference in means describes populations, not individuals.
• Long-term outcomes. Semaglutide has published cardiovascular outcomes data; a comparable outcomes dataset directly comparing the two molecules has not been published.
• Anything about tolerability ranking. Gastrointestinal adverse events dominated in both arms of both trials, and discontinuation rates were broadly similar.

As laboratory material

Everything above describes finished pharmaceutical products studied in supervised clinical settings. It characterises the molecules — their receptor profiles, half-lives and measured effects in trial populations — and that is the correct use of the literature in a research context.

For material supplied for laboratory use, the meaningful comparison is on the certificate of analysis rather than in the trial record. Both are supplied as lyophilized powder. Both are reconstituted with bacteriostatic water, with lyophilized material stored at −20 °C and reconstituted solution held at 2–8 °C and protected from light. Both are large, fatty-acylated peptides, and both are more sensitive to repeated freeze-thaw cycling than the shorter peptides in the same catalogue.

Identity confirmation matters more here than in most categories. Tirzepatide and semaglutide differ substantially in mass, so a mass-spectrometry trace on the certificate is a direct check on identity. Purity by HPLC and peptide content by nitrogen determination are the other two figures worth reading; purity alone does not tell you how much of the vial's mass is peptide rather than residual salts and water.

The short version

• Tirzepatide is a GIP-backbone molecule reaching the GLP-1 receptor, not a GLP-1 molecule with GIP added.
• Its dual agonism is unbalanced and signalling-biased — the mechanism behind its results is not settled.
• Two randomised head-to-head trials, in different populations, both favoured tirzepatide on the primary measures.
• That establishes direction, not mechanism, and the comparator dosing in SURPASS-2 remains contested.
• Trial data characterises approved medicines under supervision; for laboratory material, read the certificate of analysis.